Single-center experience with cyclosporine for treatment of idiopathic minimal change nephrotic syndrome in children

Iranian Journal of Kidney Diseases

Volumn 3, Issue 3, 2009, Pages 127-135

  Sabry, Alaa ^a   El Husseini, Amr ^a   El Dahshan, Khaled ^a   Sobh, Mohamed ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Child; Cyclosporine; Ketoconazole; Nephrotic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; KETOCONAZOLE; PREDNISOLONE; PREDNISONE; ANTIFUNGAL AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; STEROID;

ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; COST CONTROL; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HUMAN; IDIOPATHIC DISEASE; KIDNEY FUNCTION; MALE; NEPHROTIC SYNDROME; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; DRUG COMBINATION; FOLLOW UP; IMMUNOLOGY; LIPOID NEPHROSIS; PRESCHOOL CHILD; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; MALE; NEPHROSIS, LIPOID; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEROIDS;

EID: 70349935450     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Senior DS, Shaw JT. In vitro effects of fluconazole (UK-49,858) and ketoconazole on mouse lymphocyte proliferation and on Candida blastospore destruction by human polymorphonuclear leukocytes. Int J Immunopharmacol. 1988;10:169-73.
2. El-Husseini A, El-Basuony F, Mahmoud I, et al. Effect of concomitant administration of cyclosporine and ketoconazole in children with focal segmental glomerulosclerosis. Am J Nephrol. 2004;24:301-6.
3. el-Husseini A, el-Basuony F, Mahmoud I, et al. Coadministration of cyclosporine and ketoconazole in idiopathic childhood nephrosis. Pediatr Nephrol. 2004;19:976-81.
4. El-Husseini A, El-Basuony F, Mahmoud I, et al. Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome. Eur J Clin Pharmacol. 2006;62:3-8.
5. Sobh MA, Hamdy AF, El Agroudy AE, et al. Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences. Am J Kidney Dis. 2001;37:510-7.
6. Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet. 1997;32:357-67.
7. Dudzik B, Kaczmarczyk I, Radziszewski A, Sulowicz W. [Use of Cyclosporine A and new immunosuppressive drugs in the therapy of glomerulonephritis]. Przegl Lek. 2001;58:798-804. Polish.
8. Meyrier A, Condamin MC, Simon P. Treatment with cyclosporine of adult idiopathic nephrotic syndrome resistant to corticosteroids and other immunosuppressants. Transplant Proc. 1988;20:259-61.
9. Fujinaga S, Ohtomo Y, Someya T, Shimizu T, Yamashiro Y, Kaneko K. Is single-daily low-dose cyclosporine therapy really effective in children with idiopathic frequent-relapsing nephrotic syndrome? Clin Nephrol. 2008;69:84-9.
10. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroiddependent nephrotic syndrome. Am J Kidney Dis. 2003;42:1114-20.
11. Niaudet P. Nephrotic syndrome in children. Curr Opin Pediatr. 1993;5:174-9.
12. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2:556-60.
13. [No authors listed]. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981;98:561-4.
14. Meyrier A, Niaudet P, Brodehl J. Optimal use of sandimmun in nephrotic syndrome. Berlin: Springer; 1992.
15. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimalchange nephrotic syndrome. Nephrol Dial Transplant. 2003;18:245-8.
16. Lim DG, Joe IY, Park YH, et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl Immunol. 2007;18:94-100.
17. Tejani AT, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. 1988;33:729-34.
18. Hulton SA, Shah V, Byrne MR, Morgan G, Barratt TM, Dillon MJ. Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome. Pediatr Nephrol. 1994;8:135-9.
19. Zieste R, Derks FHM, Schalekamp MADH, Weimar W. Cyclosporine and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy. In: Tejani A, editor. Cyclosporin in the therapy of renal disease. New York: Karger; 1995. p. 6-18.
20. Wyszynska T, Ksiazek J, Wieteska-Klimczak A, Gorzkowska-Paczwa M, Dorywalski T, Tysarowska A. [Evaluation of the efficacy of cyclosporine A treatment in idiopathic nephrotic syndrome in children]. Pol Merkur Lekarski. 2001;11:140-3. Polish.
21. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol. 1992;6:1-3.
22. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994;125:981-6.
23. Lagrue C, Laurent J, Belghiti D, Robeva R. Cyclosporin and idiopathic nephrotic syndrome. Lancet. 1986;2:692-3.
24. Tejani A, Suthanthiran M, Pomrantz A. A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children. Nephron. 1991;59:96-9.
25. Hino S, Takemura T, Okada M, et al. Follow-up study of children with nephrotic syndrome treated with a longterm moderate dose of cyclosporine. Am J Kidney Dis. 1998;31:932-9.
26. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43:1377-84.
27. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008;23:2013-20.
28. Barclay PG, Allen RD, Stewart JH, Ng K, Chapman JR. Costs of immunosuppressive therapies used in renal transplantation. Transplant Proc. 1992;24:165-6.
29. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995;333:628-33.
30. First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. Transplantation. 1993;55:1000-4.
31. Butman SM, Wild JC, Nolan PE, et al. Prospective study of the safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant. 1991;10:351-8.
32. Kanda N, Enomoto U, Watanabe S. Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol. 2001;117:1635-46.
33. Klein M, Radhakrishan J, Appel G. Cyclosporine treatment of glomerular diseases. Ann Rev Med. 1999;50:1-15.
34. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation. 1991;51:365-70.
35. Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplant Proc. 1988;20:330-8.